Safety profile of a new generation of cholesterol-lowering drugs / Complaints that a new psoriasis treatment could aggravate the condition / Eye inflammation linked to a novel immunosuppressant for atopic dermatitis.
QuarterWatch™ Reports
An independent perspective on emerging drug risks
QuarterWatch™ is published four times a year as a public service to provide an independent perspective on emerging drug risks. This scientific publication uses as its primary source recently released reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).